ION BEAM APPLICATIONS (IBAB.BR) Stock Fundamental Analysis

Europe • Euronext Brussels • EBR:IBAB • BE0003766806

15.28 EUR
0 (0%)
Last: Feb 11, 2026, 05:29 PM
Fundamental Rating

4

Taking everything into account, IBAB scores 4 out of 10 in our fundamental rating. IBAB was compared to 63 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IBAB while its profitability can be described as average. IBAB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year IBAB was profitable.
  • In the past year IBAB had a positive cash flow from operations.
  • Of the past 5 years IBAB 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: IBAB reported negative operating cash flow in multiple years.
IBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFIBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

  • IBAB has a Return On Assets (2.71%) which is in line with its industry peers.
  • IBAB has a better Return On Equity (14.29%) than 77.78% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.54%, IBAB belongs to the best of the industry, outperforming 92.06% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for IBAB is below the industry average of 9.98%.
  • The last Return On Invested Capital (15.54%) for IBAB is above the 3 year average (6.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.71%
ROE 14.29%
ROIC 15.54%
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.2%
ROIC(5y)6.71%
IBAB.BR Yearly ROA, ROE, ROICIBAB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 -30

1.3 Margins

  • IBAB has a Profit Margin (2.85%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of IBAB has declined.
  • IBAB has a Operating Margin of 6.48%. This is comparable to the rest of the industry: IBAB outperforms 42.86% of its industry peers.
  • IBAB's Operating Margin has improved in the last couple of years.
  • The Gross Margin of IBAB (31.21%) is worse than 84.13% of its industry peers.
  • In the last couple of years the Gross Margin of IBAB has remained more or less at the same level.
Industry RankSector Rank
OM 6.48%
PM (TTM) 2.85%
GM 31.21%
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
IBAB.BR Yearly Profit, Operating, Gross MarginsIBAB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IBAB is creating value.
  • IBAB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IBAB has been reduced compared to 5 years ago.
  • Compared to 1 year ago, IBAB has a worse debt to assets ratio.
IBAB.BR Yearly Shares OutstandingIBAB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IBAB.BR Yearly Total Debt VS Total AssetsIBAB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.77, we must say that IBAB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of IBAB (1.77) is worse than 63.49% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that IBAB is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.23, IBAB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 1.77
ROIC/WACC2.09
WACC7.45%
IBAB.BR Yearly LT Debt VS Equity VS FCFIBAB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • IBAB has a Current Ratio of 0.94. This is a bad value and indicates that IBAB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of IBAB (0.94) is worse than 84.13% of its industry peers.
  • IBAB has a Quick Ratio of 0.94. This is a bad value and indicates that IBAB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.62, IBAB is doing worse than 82.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.62
IBAB.BR Yearly Current Assets VS Current LiabilitesIBAB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 112.86% over the past year.
  • The Earnings Per Share has been growing slightly by 3.99% on average over the past years.
  • Looking at the last year, IBAB shows a quite strong growth in Revenue. The Revenue has grown by 15.96% in the last year.
  • Measured over the past years, IBAB shows a quite strong growth in Revenue. The Revenue has been growing by 12.01% on average per year.
EPS 1Y (TTM)112.86%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%75.35%
Revenue 1Y (TTM)15.96%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%47.7%

3.2 Future

  • IBAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.72% yearly.
  • IBAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.63% yearly.
EPS Next Y141.9%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
EPS Next 5Y58.72%
Revenue Next Year23.68%
Revenue Next 2Y13.14%
Revenue Next 3Y10.36%
Revenue Next 5Y2.63%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
IBAB.BR Yearly Revenue VS EstimatesIBAB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
IBAB.BR Yearly EPS VS EstimatesIBAB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1 1.5

5

4. Valuation

4.1 Price/Earnings Ratio

  • IBAB is valuated quite expensively with a Price/Earnings ratio of 26.81.
  • Based on the Price/Earnings ratio, IBAB is valued a bit cheaper than the industry average as 61.90% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 28.03. IBAB is around the same levels.
  • A Price/Forward Earnings ratio of 14.47 indicates a correct valuation of IBAB.
  • 77.78% of the companies in the same industry are more expensive than IBAB, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, IBAB is valued a bit cheaper.
Industry RankSector Rank
PE 26.81
Fwd PE 14.47
IBAB.BR Price Earnings VS Forward Price EarningsIBAB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • IBAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBAB is cheaper than 80.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.18
IBAB.BR Per share dataIBAB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • IBAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as IBAB's earnings are expected to grow with 67.72% in the coming years.
PEG (NY)0.19
PEG (5Y)6.73
EPS Next 2Y109.12%
EPS Next 3Y67.72%

3

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.07%, IBAB has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.97, IBAB pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.80, IBAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.07%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IBAB.BR Yearly Dividends per shareIBAB.BR Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.05 0.1 0.15 0.2

5.3 Sustainability

  • 8.05% of the earnings are spent on dividend by IBAB. This is a low number and sustainable payout ratio.
DP8.05%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
IBAB.BR Yearly Income VS Free CF VS DividendIBAB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M
IBAB.BR Dividend Payout.IBAB.BR Dividend Payout, showing the Payout Ratio.IBAB.BR Dividend Payout.PayoutRetained Earnings

ION BEAM APPLICATIONS

EBR:IBAB (2/11/2026, 5:29:58 PM)

15.28

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-20
Earnings (Next)03-27
Inst Owners27.85%
Inst Owner ChangeN/A
Ins Owners0.71%
Ins Owner ChangeN/A
Market Cap462.68M
Revenue(TTM)596.63M
Net Income(TTM)17.00M
Analysts80
Price Target15.56 (1.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.07%
Yearly Dividend0.17
Dividend Growth(5Y)N/A
DP8.05%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.4%
PT rev (3m)3.98%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-13.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.04%
Valuation
Industry RankSector Rank
PE 26.81
Fwd PE 14.47
P/S 0.78
P/FCF N/A
P/OCF 166.19
P/B 3.89
P/tB 4.9
EV/EBITDA 10.18
EPS(TTM)0.57
EY3.73%
EPS(NY)1.06
Fwd EY6.91%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.09
OCFY0.6%
SpS19.7
BVpS3.93
TBVpS3.12
PEG (NY)0.19
PEG (5Y)6.73
Graham Number7.1
Profitability
Industry RankSector Rank
ROA 2.71%
ROE 14.29%
ROCE 25.19%
ROIC 15.54%
ROICexc 16.45%
ROICexgc 19.79%
OM 6.48%
PM (TTM) 2.85%
GM 31.21%
FCFM N/A
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.2%
ROIC(5y)6.71%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.19%
ROCE(5y)10.93%
ROICexgc growth 3YN/A
ROICexgc growth 5Y52.5%
ROICexc growth 3Y-88.2%
ROICexc growth 5Y50.32%
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
F-Score7
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA 0.54
Cap/Depr 65.94%
Cap/Sales 1.38%
Interest Coverage 250
Cash Conversion 5.44%
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.62
Altman-Z 1.77
F-Score7
WACC7.45%
ROIC/WACC2.09
Cap/Depr(3y)79.57%
Cap/Depr(5y)64.6%
Cap/Sales(3y)2.05%
Cap/Sales(5y)1.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.86%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%75.35%
EPS Next Y141.9%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
EPS Next 5Y58.72%
Revenue 1Y (TTM)15.96%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%47.7%
Revenue Next Year23.68%
Revenue Next 2Y13.14%
Revenue Next 3Y10.36%
Revenue Next 5Y2.63%
EBIT growth 1Y38.72%
EBIT growth 3Y27.16%
EBIT growth 5Y65.71%
EBIT Next Year221.54%
EBIT Next 3Y67.42%
EBIT Next 5Y52.9%
FCF growth 1Y90.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.87%
OCF growth 3YN/A
OCF growth 5YN/A

ION BEAM APPLICATIONS / IBAB.BR FAQ

Can you provide the ChartMill fundamental rating for ION BEAM APPLICATIONS?

ChartMill assigns a fundamental rating of 4 / 10 to IBAB.BR.


What is the valuation status of ION BEAM APPLICATIONS (IBAB.BR) stock?

ChartMill assigns a valuation rating of 5 / 10 to ION BEAM APPLICATIONS (IBAB.BR). This can be considered as Fairly Valued.


How profitable is ION BEAM APPLICATIONS (IBAB.BR) stock?

ION BEAM APPLICATIONS (IBAB.BR) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for IBAB stock?

The Price/Earnings (PE) ratio for ION BEAM APPLICATIONS (IBAB.BR) is 26.81 and the Price/Book (PB) ratio is 3.89.


Can you provide the dividend sustainability for IBAB stock?

The dividend rating of ION BEAM APPLICATIONS (IBAB.BR) is 3 / 10 and the dividend payout ratio is 8.05%.